These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8985818)

  • 61. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders.
    Sarrazin C; Rouzier R; Wagner F; Forestier N; Larrey D; Gupta SK; Hussain M; Shah A; Cutler D; Zhang J; Zeuzem S
    Gastroenterology; 2007 Apr; 132(4):1270-8. PubMed ID: 17408662
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Serum transaminase elevations during pegylated interferon treatment of chronic HCV hepatitis probably induced by polyethylene glycol.
    Caroleo B; Gallelli L; Staltari O; De Sarro G; Guadagnino V
    Intervirology; 2008; 51(6):407-9. PubMed ID: 19258719
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience.
    Schvarcz R; Ando Y; Sönnerborg A; Weiland O
    J Hepatol; 1995; 23 Suppl 2():17-21. PubMed ID: 8720289
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Treatment of hepatitis C in hemodialysis patients with pegylated interferon alpha-2a as monotherapy.
    Sikole A; Dzekova P; Selja N; Gaseva M; Nikolov IG; Zabzun M; Muharemi S; Asani A; Amitov V; Mena S; Grunevska V; Ivanovski L; Polenakovic M
    Ren Fail; 2007; 29(8):961-6. PubMed ID: 18067041
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.
    Zeuzem S; Buggisch P; Agarwal K; Marcellin P; Sereni D; Klinker H; Moreno C; Zarski JP; Horsmans Y; Mo H; Arterburn S; Knox S; Oldach D; McHutchison JG; Manns MP; Foster GR
    Hepatology; 2012 Mar; 55(3):749-58. PubMed ID: 22006408
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effect of alcohol intake on the efficacy of interferon therapy in patients with chronic hepatitis C as evaluated by multivariate logistic regression analysis.
    Mochida S; Ohnishi K; Matsuo S; Kakihara K; Fujiwara K
    Alcohol Clin Exp Res; 1996 Dec; 20(9 Suppl):371A-377A. PubMed ID: 8986241
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Acute hepatitis C: a 24-week course of pegylated interferon α-2b versus a 12-week course of pegylated interferon α-2b alone or with ribavirin.
    Santantonio T; Fasano M; Sagnelli E; Tundo P; Babudieri S; Fabris P; Toti M; Di Perri G; Marino N; Pizzigallo E; Angarano G;
    Hepatology; 2014 Jun; 59(6):2101-9. PubMed ID: 24442928
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Evaluation of long-term efficacy of interferon alpha-2b and ribavirin in combination in naive patients with chronic hepatitis C: an Italian multicenter experience. Ribavirin-Interferon in Chronic Hepatitis Italian Group Investigators.
    Barbaro G; Di Lorenzo G; Soldini M; Giancaspro G; Pellicelli A; Grisorio B; Barbarini G
    J Hepatol; 2000 Sep; 33(3):448-55. PubMed ID: 11020001
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Multicenter study of pegylated interferon α-2a monotherapy for hepatitis C virus-infected patients on hemodialysis: REACH study.
    Kikuchi K; Akiba T; Nitta K; Masakane I; Ando R; Izumi N; Atsukawa M; Yamazaki C; Kato F; Hotta N; Tominaga Y; Orito E; Hora K; Nagasawa M; Kasahara H; Kawaguchi M; Kimura H; Ikebe N; Kawanishi H; Moriishi M; Shigemoto K; Harada T; Hirakata H; Watanabe H; Nosaki T; Tsubouchi H; Imawari M; Akizawa T
    Ther Apher Dial; 2014 Dec; 18(6):603-11. PubMed ID: 25196061
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialyzed patients.
    Pol S; Thiers V; Carnot F; Zins B; Romeo R; Berthelot P; Bréchot C
    Kidney Int; 1995 May; 47(5):1412-8. PubMed ID: 7637270
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response.
    Espinosa M; Rodriguez M; Martin-Malo A; Alvarez de Lara MA; Gonzalez R; Lopez-Rubio F; de la Mata M; Aljama P
    Clin Nephrol; 2001 Mar; 55(3):220-6. PubMed ID: 11316242
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Interferon-alpha therapy within the first year after acute hepatitis C infection in hemodialysis patients: efficacy and tolerance.
    Rocha CM; Perez RM; Narciso JL; Ferreira AP; Lemos LB; Medina-Pestana JO; Silva AE; Ferraz ML
    Eur J Gastroenterol Hepatol; 2007 Feb; 19(2):119-23. PubMed ID: 17272996
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Interferon-gamma with peginterferon alpha-2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI).
    Couzigou P; Pérusat S; Bourlière M; Trimoulet P; Poynard T; Leroy V; Marcellin P; Foucher J; Bronowicki JP; Chêne G;
    J Gastroenterol Hepatol; 2013 Feb; 28(2):329-34. PubMed ID: 23190183
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effect of hepatitis G virus infection on chronic hepatitis C.
    Tanaka E; Alter HJ; Nakatsuji Y; Shih JW; Kim JP; Matsumoto A; Kobayashi M; Kiyosawa K
    Ann Intern Med; 1996 Nov; 125(9):740-3. PubMed ID: 8929008
    [TBL] [Abstract][Full Text] [Related]  

  • 75. HCV viraemia is more important than genotype as a predictor of response to interferon in Sicily (southern Italy).
    Magrin S; Craxi A; Fabiano C; Marino L; Fiorentino G; Lo Iacono O; Volpes R; Di Marco V; Almasio P; Vaccaro A; Urdea MS; Wilber JC; Bonura C; Gianguzza F; Capursi V; Filiberti S; Stuyver L; Pagliaro L
    J Hepatol; 1996 Nov; 25(5):583-90. PubMed ID: 8938531
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A patient with acute hepatitis C and possible IFN toxicity.
    Licata A; Di Marco V; Craxì A
    Dig Liver Dis; 2003 May; 35(5):372-3. PubMed ID: 12846412
    [No Abstract]   [Full Text] [Related]  

  • 77. Rise of plasma myeloperoxidase during interferon therapy.
    Nakamuta M; Ohashi M; Fukutomi T; Tanabe Y; Hiroshige K; Nawata H
    J Gastroenterol Hepatol; 1995; 10(3):277-80. PubMed ID: 7548803
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [IFN-alpha-induced psoriatic arthritis and HCV-related liver cirrhosis. Therapeutic options and patient's opinion].
    Cauli A; Porru G; Vacca A; Mameli A; Ibba V; Mura V; Piga M; Mathieu A
    Reumatismo; 2008; 60(1):57-60. PubMed ID: 18432326
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Remote abscess formation during interferon-alpha therapy for viral hepatitis.
    Gogos CA; Starakis JK; Bassaris HP; Skoutelis AT
    Clin Microbiol Infect; 2003 Jun; 9(6):540-2. PubMed ID: 12848731
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Psoriatic arthritis and alpha-interferon.
    Olivieri I; Padula A; Ciancio G; La Civita L
    Scand J Rheumatol; 2001; 30(3):175. PubMed ID: 11469531
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.